Cagrilintid + Semaglutid-Mischung (CagriSema)

Produktübersicht

Developed as a potential successor to Ozempic, Mounjaro, and Wegovy, CagriSema combines two mechanisms: cagrilintide promotes satiety, slows gastric emptying, and suppresses postprandial glucagon release via amylin/calcitonin receptors; semaglutide enhances glucose-dependent insulin secretion, suppresses appetite via CNS pathways, and delays gastric emptying via GLP-1 receptors. Phase II weight loss averaged 15.6% after 32 weeks, comparable to tirzepatide. Multiple Phase III trials are ongoing including populations with kidney disease.

Mechanismus der Wirkung

Cagrilintide and semaglutide act on complementary neuroendocrine circuits. Cagrilintide mimics amylin to promote satiety and suppress glucagon. Semaglutide activates GLP-1 receptors for insulin secretion and appetite suppression. Together, their converging mechanisms amplify appetite regulation, energy intake reduction, and glycemic improvements exceeding monotherapy results.

Wichtigste Vorteile

Überlegener Gewichtsverlust — Synergistic weight reduction up to 15–17% over 20–32 weeks, exceeding either component alone. Comparable efficacy to tirzepatide.

Enhanced Glycemic Control — Significantly improved HbA1c compared to cagrilintide alone. Complementary insulin and glucagon regulation for comprehensive blood sugar management.

Favorable Safety Profile — Side effects are mild to moderate, mainly gastrointestinal (nausea, vomiting, diarrhea), diminishing over time. No instances of severe hypoglycemia in trials.

Once-Weekly Convenience — Single weekly injection delivers dual-receptor activation for sustained metabolic benefits with minimal treatment burden.

Referenzen

1. Enebo LB, et al. Safety and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management. *Lancet.* 2021;397(10286):1736–1748.
2. Wadden TA, et al. Lifestyle modification approaches for the treatment of obesity in adults. *Am Psychol.* 2020;75:235–251.
3. Kollewe J. Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled 'obsolete'. *The Guardian.* 2026.